Why I’d ditch buy-to-let property and buy these 2 FTSE 100 growth shares today

I think that these two FTSE 100 (INDEXFTSE:UKX) shares could offer long-term growth potential.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With house prices being close to record levels when compared to average incomes, the capital growth potential of buy-to-let investments may be somewhat limited.

By contrast, the FTSE 100 appears to offer significant long-term growth prospects. A number of its members trade on fair valuations, and are expected to post improving financial performances as they deliver on their strategies.

Here are two prime examples of such companies. Buying them now could be a worthwhile move, since they may outperform buy-to-let investments in the coming years.

AstraZeneca

The recent third-quarter update from AstraZeneca (LSE: AZN) highlighted the rapid pace of growth that the FTSE 100 pharmaceutical company is experiencing. Its core earnings increased by 36% in the quarter compared to the same period of the prior year. This highlights the success of its strategy, with the company’s pipeline suggesting that a rapid rate of growth may be maintained over the long run.

As a result of its improving financial performance, the stock now trades on a price-to-earnings (P/E) ratio of around 27. While this may seem to be high, the stock is forecast to post a rise in its bottom line of 20% next year. This could justify its current valuation – especially since its balance sheet and cash flow provide the financial firepower it needs to maintain a high level of investment in its pipeline.

AstraZeneca’s defensive characteristics may appeal to investors in 2020. The company’s financial performance is less dependent on the wider economy than is the case for many of its FTSE 100 peers. As such, now could be the right time to buy a slice of it, with its current growth strategy set to lead to an improving share price performance.

Burberry

Another FTSE 100 share that has a solid growth strategy is Burberry (LSE: BRBY). The premium fashion business has changed its senior management team in the last few years, and is embarking on major strategy shifts that seem to be working well.

For example, it is working to move even more upmarket, is cutting costs, has launched a wide range of new products under its new creative head that are proving popular with consumers, and is seeking to boost its sales through the use of social media and influencers. Its focus on its highest-end  luxury products also involves store closures and store upgrades, all of it potentially leading to improving financial performance.

Although Burberry’s share price now trades on a P/E ratio of 24, it is forecast to produce a 10% rise in net profit next year. Beyond this, its exposure to fast-growing consumer markets across Asia could strengthen its investment appeal. Therefore, while there may be cheaper stocks available in the FTSE 100, the company’s financial prospects and its economic moat that is derived from a high degree of brand loyalty could lead to significant capital growth in the coming years.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended AstraZeneca and Burberry. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Sunrise over Earth
Investing Articles

Meet the ex-penny share up 109% that has topped Rolls-Royce and Nvidia in 2025

The share price of this investment trust has gone from pennies to above £1 over the past couple of years.…

Read more »

House models and one with REIT - standing for real estate investment trust - written on it.
Investing Articles

1 of the FTSE 100’s most reliable dividend stocks for me to buy now?

With most dividend stocks with 6.5% yields, there's a problem with the underlying business. But LondonMetric Property is a rare…

Read more »

Investing Articles

Is 2026 the year to consider buying oil stocks?

The time to buy cyclical stocks is when they're out of fashion with investors. And that looks to be the…

Read more »

ISA coins
Investing Articles

3 reasons I’m skipping a Cash ISA in 2026

Putting money into a Cash ISA can feel safe. But in 2026 and beyond, that comfort could come at a…

Read more »

US Stock

I asked ChatGPT if the Tesla share price could outperform Nvidia in 2026, with this result!

Jon Smith considers the performance of the Tesla share price against Nvidia stock and compares his view for next year…

Read more »

Investing Articles

Greggs: is this FTSE 250 stock about to crash again in 2026?

After this FTSE 250 stock crashed in 2025, our writer wonders if it will do the same in 2026. Or…

Read more »

Investing Articles

7%+ yields! Here are 3 major UK dividend share forecasts for 2026 and beyond

Mark Hartley checks forecasts and considers the long-term passive income potential of three of the UK's most popular dividend shares.

Read more »

Hand is turning a dice and changes the direction of an arrow symbolizing that the value of an ETF (Exchange Traded Fund) is going up (or vice versa)
Investing Articles

2 top ETFs to consider for an ISA in 2026

Here are two very different ETFs -- one set to ride the global robotics boom, the other offering a juicy…

Read more »